Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The coronary artery endothelium is the inner cellular lining of the coronary arteries. It is composed of specialized endothelial cells that maintain vascular homeostasis by modulating vessel tone (via release of nitric oxide, prostacyclin, endothelin-1, and other substances), controlling barrier function and selective permeability, regulating thrombosis and fibrinolysis, and directing inflammatory responses. Endothelial dysfunction in the coronary arteries is a critical early determinant of atherosclerosis and ischemic heart disease, impairing vasodilation, increasing pro-thrombotic and pro-inflammatory signals, and promoting plaque development and instability.
Not applicable for drugs specifically binding to "coronary artery endothelium" as a molecular target. Mechanisms relevant to endothelial cells include improving nitric oxide bioavailability, reducing oxidative stress, inhibiting vasoconstrictors, or ameliorating endothelial dysfunction.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coronary artery endothelium.